Skip to main content

Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.

Publication ,  Journal Article
George, DJ
Published in: Clin Adv Hematol Oncol
September 2017

Duke Scholars

Published In

Clin Adv Hematol Oncol

ISSN

1543-0790

Publication Date

September 2017

Volume

15

Issue

9

Start / End Page

690 / 694

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Symptom Assessment
  • Radium
  • Prostatic Neoplasms, Castration-Resistant
  • Patient Selection
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Metastasis
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
George, D. J. (2017). Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol, 15(9), 690–694.
George, Daniel J. “Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.Clin Adv Hematol Oncol 15, no. 9 (September 2017): 690–94.
George, Daniel J. “Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.Clin Adv Hematol Oncol, vol. 15, no. 9, Sept. 2017, pp. 690–94.
George DJ. Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2017 Sep;15(9):690–694.

Published In

Clin Adv Hematol Oncol

ISSN

1543-0790

Publication Date

September 2017

Volume

15

Issue

9

Start / End Page

690 / 694

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Symptom Assessment
  • Radium
  • Prostatic Neoplasms, Castration-Resistant
  • Patient Selection
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Metastasis
  • Male
  • Humans